We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The latest Ebola outbreak in the Democratic Republic of Congo will again turn to Merck & Co’s experimental rVSV-ZEBOV that was so successful in attacking the last outbreak.